Reported Earlier, Vanda Says Phase III HETLIOZ Study Met Primary Endpoint In Delayed Sleep-Wake Phase Disorder, Shifting Sleep Onset 37.1 Minutes Earlier Versus Placebo; sNDA Planned

뉴스 본문을 불러오고 있어요.

Reported Earlier, Vanda Says Phase III HETLIOZ Study Met Primary Endpoint In Delayed Sleep-Wake Phase Disorder, Shifting Sleep Onset 37.1 Minutes Earlier Versus Placebo; sNDA Planned | 웨이프 WAPE

Reported Earlier, Vanda Says Phase III HETLIOZ Study Met Primary Endpoint In Delayed Sleep-Wake Phase Disorder, Shifting Sleep Onset 37.1 Minutes Earlier Versus Placebo; sNDA Planned

기사 요약

관련 종목

댓글 —